
Haemonetics (HAE) Stock Forecast & Price Target
Haemonetics (HAE) Analyst Ratings
Bulls say
Haemonetics is supported by strong fundamental momentum, as F2Q27 revenue rose 9% reported and 10% organic to $357.8 million while adjusted EPS of $1.35 beat expectations, with all segments outperforming. Its Plasma franchise is the key growth engine, aided by high-single-digit global collection growth, Persona PLUS adoption, and the return of CSL as a customer across ~300 U.S. centers by calendar year 2027, which should add durable recurring revenue. The company also benefits from improving profitability and cash generation, including a Plasma operating margin of roughly 34% to 35%, quarterly free cash flow of $103.8 million, and FCF conversion above 80% guided for FY27.
Bears say
Haemonetics is exposed to meaningful regulatory and operational risk because it operates in a highly scrutinized FDA environment, where adverse observations, warning letters, or product recalls could quickly pressure sales and investor confidence. The company also sole-sources some raw materials and components, creating vulnerability to supply shortages that could disrupt production and cause lost sales, while its reliance on cost-cutting and efficiency programs adds execution risk if the expected benefits fail to materialize. On top of that, the MedTech sector’s heavy intellectual property burden raises the chance of infringement disputes or lengthy, expensive litigation, further threatening margins and the company’s overall financial profile.
This aggregate rating is based on analysts' research of Haemonetics and is not a guaranteed prediction by Public.com or investment advice.
Haemonetics (HAE) Analyst Forecast & Price Prediction
Start investing in Haemonetics (HAE)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Haemonetics (HAE) Forecast
Haemonetics (HAE) Analyst Forecast & Price Prediction
Start investing in Haemonetics (HAE)
Order type
Buy in
Order amount
Est. shares
0 shares